← Search & browse all drugs

benralizumab

R03DX10

Forms & Strengths

Subcutaneous injection: 30 mg/1 mL pre-filled syringe
Subcutaneous injection: 30 mg/1 mL auto-injector

Adult Dosing

Severe eosinophilic asthma: 30 mg subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter
Chronic rhinosinusitis with nasal polyps: 30 mg subcutaneously every 4 weeks

Pediatric Dosing

Severe eosinophilic asthma (adolescents aged 12 years and older): 30 mg subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter
Safety and efficacy in children younger than 12 years have not been established

Indications

Add-on maintenance treatment of severe asthma with an eosinophilic phenotype in adults and pediatric patients aged 12 years and older
Add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults aged 18 years and older

Mechanism of Action

Humanized monoclonal antibody (IgG1 kappa) that binds directly to the alpha subunit of the human interleukin-5 receptor (IL-5Ralpha)
Prevents IL-5 from binding to its receptor on eosinophils and basophils
Recruits natural killer cells to induce rapid and nearly complete depletion of eosinophils and basophils via antibody-dependent cell-mediated cytotoxicity (ADCC)

Contraindications

Known hypersensitivity to benralizumab or any of its excipients (history of anaphylaxis to the drug)

Adverse Reactions

Headache
Pharyngitis
Injection site reactions (pain, erythema, pruritus)
Hypersensitivity reactions (anaphylaxis, angioedema, urticaria, rash)

Drug Interactions

Formal clinical drug interaction studies have not been performed
Reduction of high-dose systemic corticosteroids may be achieved after initiation, but abrupt discontinuation should be avoided
Live attenuated vaccines should generally be avoided during treatment

Curated Content: Needs Vetting Before Put to Clinical Use